Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06420973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Peking University Cancer Hospital & Institute to Peking University Cancer Hospital & Institute
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.
Trial Details
NCT Number NCT06420973
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions
(from sponsor)		 Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Related terms Fallopian Tube Neoplasms, Ovarian Neoplasms
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov